date:May 28, 2015
In this randomized, double blind placebo-controlled clinical study, published in the Iranian Journal of Pharmaceutical Research, Curcumin C3 Complex (from Sabinsa) showed promising results in reducing the serum levels of triglycerides, low-density lipoprotein cholesterol and VLDL cholesterol in subjects with coronary artery disease (CAD). During eight week study, 33 subjects with CAD were administered four 500 mg/d capsules of Curcumin C3 Complex or matching placebo for two months in addition